SCHEMBL23639284

SCHEMBL23639284

CCC(O)c1ccncc1Cl

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.42
CYP3A4 P08684 3/20 0.42
SLC6A2 P23975 3/20 0.42
SLC6A4 P31645 3/20 0.42
SLC6A3 Q01959 3/20 0.42
KCNH2 Q12809 3/20 0.42
GAA P10253 1/20 0.39
LMNA P02545 1/20 0.35
ADRA2C P18825 1/20 0.35
ADRB2 P07550 2/20 0.34
ADRB1 P08588 2/20 0.34
AOC3 Q16853 1/20 0.34
RPS6KA3 P51812 1/20 0.34
PDE2A O00408 1/20 0.33
NFKB1 P19838 1/20 0.33
HIF1A Q16665 1/20 0.33
CYP51A1 Q16850 2/20 0.33
RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8263256 0.85 LMNA (0.35) CYP2D6CYP3A4SLC6A2SLC6A4SLC6A3
SCHEMBL13316246 0.81 CYP3A4 (0.40) CYP2D6CYP3A4SLC6A2SLC6A4SLC6A3
SCHEMBL23219772 0.79 GAA (0.41) CYP2D6CYP3A4SLC6A2SLC6A4SLC6A3
SCHEMBL2111078 0.79 GAA (0.43) CYP2D6CYP3A4SLC6A2SLC6A4SLC6A3
SCHEMBL2495086 0.79 GAA (0.43) CYP2D6CYP3A4SLC6A2SLC6A4SLC6A3
SCHEMBL13385945 0.78 PDE2A (0.47) KCNH2LMNARPS6KA3PDE2ACYP51A1
SCHEMBL15157564 0.78 GAA (0.44) CYP2D6CYP3A4SLC6A2SLC6A4SLC6A3
SCHEMBL20524310 0.78 LMNA (0.35) CYP3A4GAALMNARPS6KA3PDE2A
SCHEMBL27826383 0.77 CYP3A4 (0.39) CYP2D6CYP3A4SLC6A2SLC6A4SLC6A3
SCHEMBL14887431 0.76 CYP3A4 (0.44) CYP2D6CYP3A4SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018131-A1 MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF FORESEE PHARMACEUTICALS USA, INC. 2024-01-18 US disclosed
US-20240018131-A1 MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF FORESEE PHARMACEUTICALS USA, INC. 2024-01-18 US disclosed
US-11739080-B2 Matrix metalloproteinase (MMP) inhibitors and methods of use thereof FORESEE PHARMACEUTICALS USA, INC. (US) 2023-08-29 US disclosed
US-11739080-B2 Matrix metalloproteinase (MMP) inhibitors and methods of use thereof FORESEE PHARMACEUTICALS USA, INC. (US) 2023-08-29 US disclosed
US-20210214340-A1 MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF FORESEE PHARMACEUTICALS USA, INC. 2021-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210214340-A1 MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF MMP12, MMP1, MMP11 CYP2D6 2306/4885CYP3A4 1727/4885SLC6A2 3062/4885
US-20240018131-A1 MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF MMP12, MMP1, MMP11 CYP2D6 2306/4885CYP3A4 1727/4885SLC6A2 3062/4885
US-11739080-B2 Matrix metalloproteinase (MMP) inhibitors and methods of use thereof MMP12, MMP1, MMP11 CYP2D6 2306/4885CYP3A4 1727/4885SLC6A2 3062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.